Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. - Wikidata - awgldk - TriplyDB

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

http://www.wikidata.org/entity/Q50954469

about

Checkpoint Inhibitors and Their Application in Breast Cancer Cancer stem cells and immunoresistance: clinical implications and solutions Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Novel technologies and emerging biomarkers for personalized cancer immunotherapy Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment Primer on tumor immunology and cancer immunotherapy The STING pathway and the T cell-inflamed tumor microenvironment Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer Lung Cancer Gene Signatures and Clinical Perspectives Therapeutic cancer vaccines and combination immunotherapies involving vaccination Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.Molecular pathways and therapeutic targets in lung cancer Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors.Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer Trial Watch: Toll-like receptor agonists in oncological indications.Advances in adjuvant systemic therapy for non-small-cell lung cancer.Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer Current status of autologous breast tumor cell-based vaccines.Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss of X Chromosome Inactivation.Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.The immune-related role of BRAF in melanoma.Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types.Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype The host STING pathway at the interface of cancer and immunity Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

P2860

Q26745442-4A701CED-A3A9-4FDD-8BFB-EB32707FA886 Q26769757-69CD4464-F1D3-47E4-A3AE-3B70429D1B64 Q26769884-E764CEDF-2B20-450B-A8E6-B8171217BE91 Q26770780-EADBDE13-8941-4631-A07E-DE474C359A7C Q26796314-DD9ED96E-F640-4378-89E6-571DAAAEB742 Q26799117-09078C04-C6ED-4E49-B6B8-A3577785F68B Q27001126-E7D7F2E3-6649-45DE-8373-51CC2A0D2C2C Q27008371-73D89859-F11A-46A9-A2AD-F39722A9535F Q28078539-A1FFFC7E-53C8-4168-BE8B-94B6F9405551 Q28080773-95401DAD-75BE-43AC-A188-A179C4F67A7E Q28387769-F7D0B85C-2FAA-40EB-8B41-CCB653094A1D Q28397609-9A6BD177-10F0-4A89-B1D0-9DDA2BF32D30 Q28542859-0109C619-C839-4049-BFD9-32F043725C08 Q33599094-878C2BCA-3FFB-43B4-AAE4-99683FEAC479 Q33688872-29F092CD-4006-4759-A426-67E4149EEF4F Q33750137-216294B3-5E3F-41AC-952B-B025F136A49E Q33788685-C84F23F3-AFF8-4F52-AFE7-C5D7C1840E42 Q33862861-8335D44F-0504-4494-8DFE-AD3AFFE118D3 Q33878578-C7B98A73-F1E0-4FA9-8AB6-33C921E9CEB7 Q34031225-AB790982-4CBC-43D6-9E58-6FA251C27B5A Q34120040-879152A2-AF45-483A-909F-B66506D90B05 Q34338284-464F3907-DD6B-4F1C-A4D1-AD98E4A40539 Q34476337-20855C7B-5919-4F32-9C52-6441C936B9D0 Q34563201-79630C6C-067E-4430-AB67-F0C1FBA45229 Q35154214-9E09D2EB-88CE-4866-BA57-37EE3450EA11 Q35200745-E61E76CB-A854-4411-922C-46785B1265C9 Q35300077-38A9E177-F9AC-4C80-9A62-A83DDBD7D474 Q35506764-EDCA3948-FA88-4EC5-8A9A-62322A88328D Q35770643-89476287-49B8-48C6-90D7-2D3D0FA38820 Q35828560-398A3307-85F3-44C6-A48B-74591951DE09 Q35847321-D33454A7-F6EF-41D3-9785-2AB1B326E4A6 Q36051184-8AC8F6A9-1C05-4E03-86B0-CEE522F73DFB Q36110300-2584F201-6B81-41C4-9BA4-F2BA0ED5A0FE Q36534662-0D24539F-1796-484A-B82E-5F1C3CFBED0A Q36814030-8D88A22C-246D-42A8-BDE2-0F41D56D3B94 Q36925103-CF83D3C5-3EE2-4D17-A648-5EE49FD81493 Q37042237-A61E26A6-6A06-47E4-9295-28158058FC02 Q37148418-D5CFC63E-BCEF-4907-B3A1-2BCFF21AEEFB Q37279217-C9FC4AC5-14B4-40EC-A8FD-4241DA6A1A0A Q37281267-7E2425BB-CC1A-4848-AAB1-F0703EE80A3A

P2860

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

http://www.wikidata.org/entity/Q50954469

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

@en

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

@nl

type

label

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

@en

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

@nl

prefLabel

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

@en

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

@nl

P1433

Q50954469-B5C40928-C648-429B-AEDE-9994111ECDDC

P1476

Q50954469-8B69B2F0-E057-42E4-8854-1084A42090E9

P2093

Q50954469-13A0AFF8-A02D-458F-B823-D9259064890B

Q50954469-2870AF75-43A4-41FF-A1C6-6EF316D0DDD0

Q50954469-3739FBE6-0F90-40F9-9F6C-639D5FB6C84A

Q50954469-41205148-F07E-4B30-9DFD-77AF7BD1DEEC

Q50954469-499321F1-2463-4075-9830-DE4F23351F66

Q50954469-63D714FD-FBB3-454B-B358-DE6C56D69096

Q50954469-90AB34D9-D1D0-46BF-9FBB-9DF638C89D1C

Q50954469-981CC1B1-1281-4070-AB67-C83DF3745CF6

Q50954469-BA295BE6-9116-4642-B891-42CF610BEE1A

Q50954469-E10CABF7-C5C7-4FAE-8185-9236EFDC8AEC

P304

Q50954469-E41A8079-6F88-4A18-B4B3-D97C0AE4F5E2

P31

Q50954469-9CAE0BC7-E5AD-405C-A3DC-A9C7C06396AC

P356

Q50954469-DFCD8829-579C-4362-9949-DAC0AC7BAEE2

P407

Q50954469-FB0DB5C8-CC8B-49C3-8E67-5A0EBC6CB20A

P433

Q50954469-A8C0789E-5262-4B0E-B354-CADD96578BEB

P478

Q50954469-981AD7BB-C6E8-4438-AAC5-EE393B6E558A

P577

Q50954469-B2C07EC4-5AA8-4699-B9DF-10FDD92F803C

P698

Q50954469-62F8170A-BC14-4A54-991B-6C474F4A438E

P921

Q50954469-621EF190-B3AF-4263-A307-AAAFA2B9670F

P356

JCO.2012.44.3762

P1433

Journal of Clinical Oncology

P1476

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

@en

P2093

Alexander M M Eggermont

http://www.w3.org/2001/XMLSchema#string

Bart Spiessens

http://www.w3.org/2001/XMLSchema#string

Benjamin Dizier

http://www.w3.org/2001/XMLSchema#string

Fernando Ulloa-Montoya

http://www.w3.org/2001/XMLSchema#string

Frédéric F Lehmann

http://www.w3.org/2001/XMLSchema#string

Jamila Louahed

http://www.w3.org/2001/XMLSchema#string

Johan Vansteenkiste

http://www.w3.org/2001/XMLSchema#string

Olivier Gruselle

http://www.w3.org/2001/XMLSchema#string

Stefan Suciu

http://www.w3.org/2001/XMLSchema#string

Vincent G Brichard

http://www.w3.org/2001/XMLSchema#string

P304

2388-2395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.44.3762

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23715562

http://www.w3.org/2001/XMLSchema#string

P921